Published in Proc Natl Acad Sci U S A on September 12, 1995
Limbic hyperactivation during processing of neutral facial expressions in children with bipolar disorder. Proc Natl Acad Sci U S A (2006) 2.65
The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain Res (2008) 1.84
Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther (2009) 1.67
Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci (2004) 1.39
Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy. Proc Natl Acad Sci U S A (2012) 1.12
Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J Psychopharmacol (2014) 1.04
Animal models of gene-environment interactions in schizophrenia. Behav Brain Res (2009) 0.98
A rat genetic map constructed by representational difference analysis markers with suitability for large-scale typing. Proc Natl Acad Sci U S A (1996) 0.92
Consideration of species differences in developing novel molecules as cognition enhancers. Neurosci Biobehav Rev (2012) 0.87
Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions. Neuropsychopharmacology (2006) 0.86
Interaction of genotype and environment: effect of strain and housing conditions on cognitive behavior in rodent models of schizophrenia. Front Behav Neurosci (2013) 0.85
Comprehensive behavioural analysis of Long Evans and Sprague-Dawley rats reveals differential effects of housing conditions on tests relevant to neuropsychiatric disorders. PLoS One (2014) 0.82
Coordinated gene expression of neuroinflammatory and cell signaling markers in dorsolateral prefrontal cortex during human brain development and aging. PLoS One (2014) 0.81
Chronic administration of the neurotrophic agent cerebrolysin ameliorates the behavioral and morphological changes induced by neonatal ventral hippocampus lesion in a rat model of schizophrenia. J Neurosci Res (2011) 0.78
Quantitative trait locus analysis identifies rat genomic regions related to amphetamine-induced locomotion and Galpha(i3) levels in nucleus accumbens. Neuropsychopharmacology (2008) 0.78
Neonatal disconnection of the rat hippocampus: a neurodevelopmental model of schizophrenia. Dialogues Clin Neurosci (2002) 0.76
Differential Effect of the Dopamine D3 Agonist (±)-7-Hydroxy-2-(N,N-di-n-propylamino) Tetralin (7-OH-DPAT) on Motor Activity between Adult Wistar and Sprague-Dawley Rats after a Neonatal Ventral Hippocampus Lesion. Int J Med Chem (2011) 0.75
A plausible model of schizophrenia must incorporate psychological and social, as well as neuro developmental, risk factors. Dialogues Clin Neurosci (2001) 0.75
Effects of caffeine or RX821002 in rats with a neonatal ventral hippocampal lesion. Front Behav Neurosci (2014) 0.75
Cannabinoid-mediated diversity of antinociceptive efficacy of parecoxib in Wistar and Sprague Dawley rats in the chronic constriction injury model of neuropathic pain. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.75
Genetic dissection of complex traits. Science (1994) 29.54
Cellular and molecular mechanisms of drug dependence. Science (1988) 4.99
Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res (1975) 2.89
Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J Neurochem (1989) 2.75
Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci U S A (1989) 2.43
Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology (1993) 1.99
Quantitative trait loci mapping of three loci controlling morphine preference using inbred mouse strains. Nat Genet (1994) 1.82
A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci U S A (1989) 1.61
Fischer and Lewis rat strains show differential cocaine effects in conditioned place preference and behavioral sensitization but not in locomotor activity or conditioned taste aversion. J Pharmacol Exp Ther (1994) 1.28
Stress response, adrenal steroid receptor levels and corticosteroid-binding globulin levels--a comparison between Sprague-Dawley, Fischer 344 and Lewis rats. Brain Res (1993) 1.26
Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr Res (1995) 1.26
Genetic control of collagen-induced arthritis in rats: the immune response to type II collagen among susceptible and resistant strains and evidence for multiple gene control. J Immunol (1984) 1.24
Glial fibrillary acidic protein and the mesolimbic dopamine system: regulation by chronic morphine and Lewis-Fischer strain differences in the rat ventral tegmental area. J Neurochem (1993) 1.13
Differential establishment and maintenance of oral ethanol reinforced behavior in Lewis and Fischer 344 inbred rat strains. J Pharmacol Exp Ther (1988) 1.11
Corticotropin releasing hormone related behavioral and neuroendocrine responses to stress in Lewis and Fischer rats. Brain Res (1992) 1.08
Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res (1990) 1.07
Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology (1994) 1.04
Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Brain Res Dev Brain Res (1993) 1.01
Genetic approaches to the analysis of addiction processes. Trends Pharmacol Sci (1989) 1.01
Fischer and Lewis rat strains differ in basal levels of neurofilament proteins and their regulation by chronic morphine in the mesolimbic dopamine system. Synapse (1992) 0.96
Marijuana's interaction with brain reward systems: update 1991. Pharmacol Biochem Behav (1991) 0.94
Sex and strain differences in the circadian rhythm fluctuation of endocrine and immune function in the rat: implications for rodent models of autoimmune disease. J Neuroimmunol (1991) 0.94
Drugs and reinforcement mechanisms: a critical review of the catecholamine theory. Annu Rev Pharmacol Toxicol (1978) 0.93
Neurotransmitter-induced hypothalamic-pituitary-adrenal axis responsiveness is defective in inflammatory disease-susceptible Lewis rats: in vivo and in vitro studies suggesting globally defective hypothalamic secretion of corticotropin-releasing hormone. Neuroendocrinology (1992) 0.93
Strain-specific facilitation of dopamine efflux by delta 9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study. Neurosci Lett (1991) 0.90
Dopaminergic brain reward regions of Lewis and Fischer rats display different levels of tyrosine hydroxylase and other morphine- and cocaine-regulated phosphoproteins. Brain Res (1991) 0.88
Differential startle amplitude and corticosterone response in rats. Neuroendocrinology (1992) 0.87
Brain 5-hydroxytryptamine correlates of behavior in rats: strain and sex variability. Physiol Behav (1972) 0.85
Neuroendocrine, biogenic amine and behavioral responsiveness to a repeated foot-shock-induced analgesia (FSIA) stressor in Sprague-Dawley (CD) and Fischer-344 (CDF) rats. Brain Res (1986) 0.84
Hypothalamic PGE2 and cAMP production and adrenocortical activation following intraperitoneal endotoxin injection: in vivo microdialysis studies in Lewis and Fischer rats. Neuroendocrinology (1994) 0.82
Genetic differences in the development of physical dependence upon diazepam in Lewis and Fischer 344 inbred rat strains. Pharmacol Biochem Behav (1992) 0.82
Arthritis-susceptible Lewis rats fail to emerge from the stress hyporesponsive period. Brain Res Dev Brain Res (1992) 0.82
Neural basis of psychomotor stimulant and opiate reward: evidence suggesting the involvement of a common dopaminergic system. Behav Brain Res (1986) 0.79
Comparison of the expression, transcription and genomic organization of D2 dopamine receptors in outbred and inbred strains of rat. Brain Res (1992) 0.77
Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A (2001) 9.42
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry (2005) 9.23
Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry (1987) 8.81
Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry (1986) 4.34
Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex (2000) 3.37
Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cereb Cortex (1999) 3.31
Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N Engl J Med (1990) 3.10
Neuropsychological assessment of monozygotic twins discordant for schizophrenia. Arch Gen Psychiatry (1990) 3.07
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A (1997) 3.00
Evidence for abnormal cortical functional connectivity during working memory in schizophrenia. Am J Psychiatry (2001) 2.80
Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry (2000) 2.62
Noise reduction in 3D perfusion imaging by attenuating the static signal in arterial spin tagging (ASSIST). Magn Reson Med (2000) 2.58
Neurophysiological correlates of age-related changes in human motor function. Neurology (2002) 2.52
Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry (1997) 2.48
A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry (2000) 2.32
Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology (2000) 2.28
Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. Arch Gen Psychiatry (1987) 2.24
Impact of complex genetic variation in COMT on human brain function. Mol Psychiatry (2006) 2.22
H(2)(15)O PET validation of steady-state arterial spin tagging cerebral blood flow measurements in humans. Magn Reson Med (2000) 2.20
Modulation of cognition-specific cortical activity by gonadal steroids: a positron-emission tomography study in women. Proc Natl Acad Sci U S A (1997) 2.19
Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry (2003) 2.18
Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol Psychiatry (2007) 2.12
Relative risk for cognitive impairments in siblings of patients with schizophrenia. Biol Psychiatry (2001) 2.08
Schizophrenia and temporal lobe epilepsy. A neuropsychological analysis. Arch Gen Psychiatry (1994) 2.07
Relative risk of attention deficits in siblings of patients with schizophrenia. Am J Psychiatry (2000) 2.07
Genetic contributions to regional variability in human brain structure: methods and preliminary results. Neuroimage (2002) 2.01
Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology (1993) 1.99
Lateral cerebral ventricular enlargement in chronic schizophrenia. Arch Gen Psychiatry (1979) 1.94
Genetic variability of human brain size and cortical gyral patterns. Brain (1997) 1.92
Psychiatric disturbances in metachromatic leukodystrophy. Insights into the neurobiology of psychosis. Arch Neurol (1992) 1.91
Cognitive substrates of thought disorder, I: the semantic system. Am J Psychiatry (1998) 1.90
To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology (2000) 1.89
Serotonergic dysfunction, negative mood states, and response to alcohol. Alcohol Clin Exp Res (2001) 1.85
Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am J Psychiatry (1993) 1.78
The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry (1993) 1.75
Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function. Neuroscience (2003) 1.74
Genetic variants in AVPR1A linked to autism predict amygdala activation and personality traits in healthy humans. Mol Psychiatry (2008) 1.70
Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol Psychiatry (2008) 1.66
Physiological activation of a cortical network during performance of the Wisconsin Card Sorting Test: a positron emission tomography study. Neuropsychologia (1995) 1.65
COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol Psychiatry (2008) 1.63
Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage (2000) 1.63
Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Mol Psychiatry (2004) 1.62
Correction for vascular artifacts in cerebral blood flow values measured by using arterial spin tagging techniques. Magn Reson Med (1997) 1.61
The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia. Biol Psychiatry (1999) 1.60
Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. IV. Further evidence for regional and behavioral specificity. Arch Gen Psychiatry (1988) 1.58
GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol Psychiatry (2005) 1.56
Functional magnetic resonance imaging brain mapping in psychiatry: methodological issues illustrated in a study of working memory in schizophrenia. Neuropsychopharmacology (1998) 1.54
The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev Psychopathol (2000) 1.54
Genetic variation in MAOA modulates ventromedial prefrontal circuitry mediating individual differences in human personality. Mol Psychiatry (2007) 1.54
Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry (1993) 1.52
Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk. Mol Psychiatry (2008) 1.51
Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology (Berl) (1995) 1.48
Is the mechanism of prefrontal hypofunction in depression the same as in schizophrenia? Regional cerebral blood flow during cognitive activation. Br J Psychiatry (1993) 1.47
Catechol-o-methyltransferase enzyme activity and protein expression in human prefrontal cortex across the postnatal lifespan. Cereb Cortex (2006) 1.46
A comparison of rCBF patterns during letter and semantic fluency. Neuropsychology (2000) 1.45
Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res (2012) 1.44
Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. II. Role of neuroleptic treatment, attention, and mental effort. Arch Gen Psychiatry (1986) 1.42
MRI asymmetries of Broca's area: the pars triangularis and pars opercularis. Brain Lang (1998) 1.41
A quantitative analysis of smooth pursuit eye tracking in monozygotic twins discordant for schizophrenia. Arch Gen Psychiatry (1997) 1.41
Localization of epidermal growth factor receptors and putative neuroblasts in human subependymal zone. J Comp Neurol (2000) 1.40
Hemispheric control of motor function: a whole brain echo planar fMRI study. Psychiatry Res (1998) 1.38
Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia. Mol Psychiatry (2007) 1.38
Evidence that many of the DISC1 isoforms in C57BL/6J mice are also expressed in 129S6/SvEv mice. Mol Psychiatry (2007) 1.32
Relationship of birth weight to the phenotypic expression of Gilles de la Tourette's syndrome in monozygotic twins. Neurology (1992) 1.31
Reduced central serotonin transporters in alcoholism. Am J Psychiatry (1998) 1.31
Relationship of obstetric complications and differences in size of brain structures in monozygotic twin pairs discordant for schizophrenia. Am J Psychiatry (2000) 1.31
Intermediate phenotypes in schizophrenia genetics redux: is it a no brainer? Mol Psychiatry (2008) 1.30
Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology (Berl) (1997) 1.30
Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol (1997) 1.30
Operant conditioning and the orbitofrontal cortex in schizophrenic patients: unexpected evidence for intact functioning. Schizophr Res (1998) 1.28
Workshop on schizophrenia. Proc Natl Acad Sci U S A (1997) 1.28
Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia. Am J Psychiatry (2000) 1.28
Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry (2005) 1.27
Further evidence for association between ErbB4 and schizophrenia and influence on cognitive intermediate phenotypes in healthy controls. Mol Psychiatry (2006) 1.25
Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry (1996) 1.23
Presynaptic proteins in the prefrontal cortex of patients with schizophrenia and rats with abnormal prefrontal development. Mol Psychiatry (2003) 1.23
The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiatry (2001) 1.22
No difference in basal ganglia mineralization between schizophrenic and nonschizophrenic patients: a quantitative computerized tomographic study. Biol Psychiatry (1990) 1.21
Forms of memory failure in schizophrenia. J Abnorm Psychol (1992) 1.20
Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. Mol Psychiatry (2010) 1.20
Assessment of procedural learning and problem solving in schizophrenic patients by Tower of Hanoi type tasks. J Neuropsychiatry Clin Neurosci (1990) 1.20
Genetic risk of neuropsychological impairment in schizophrenia: a study of monozygotic twins discordant and concordant for the disorder. Schizophr Res (1995) 1.19
Dextroamphetamine enhances "neural network-specific" physiological signals: a positron-emission tomography rCBF study. J Neurosci (1996) 1.18
The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci (1991) 1.17
Schizophrenia as a developmental disorder of the cerebral cortex. Curr Opin Neurobiol (1998) 1.17
Duration judgements in patients with schizophrenia. Psychol Med (2003) 1.16
Neurobiology of schizophrenia. Curr Opin Neurobiol (1997) 1.16
Cerebral morphometric abnormalities in Tourette's syndrome: a quantitative MRI study of monozygotic twins. Neurology (1995) 1.15
Neuropsychological performance of monozygotic twins discordant for bipolar disorder. Biol Psychiatry (1999) 1.14
The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology (2000) 1.14
Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science (1996) 1.13
Probing prefrontal function in schizophrenia with neuropsychological paradigms. Schizophr Bull (1988) 1.13
Proton MR spectroscopic imaging without water suppression. Radiology (2000) 1.13
Psychomotor slowing, negative symptoms and dopamine receptor availability--an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients. Schizophr Res (1998) 1.12
Gender differences in cerebral blood flow as a function of cognitive state with PET. J Nucl Med (1996) 1.11
Localized echo-volume imaging methods for functional MRI. J Magn Reson Imaging (1997) 1.11
Cerebellar pathology in schizophrenia: a controlled postmortem study. Am J Psychiatry (1980) 1.11
Cerebral ventricular size in major depressive disorder: association with delusional symptoms. Biol Psychiatry (1983) 1.11
Temporal lobe pathology in schizophrenia: a quantitative magnetic resonance imaging study. Am J Psychiatry (1989) 1.11
Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biol Psychiatry (1998) 1.10